



Biogen to Participate in the Stifel 2023 CNS Days

March 17, 2023

Cambridge, MA, -- [Biogen Inc.](#) (Nasdaq: BII) announced today that Priya Singhal, M.D., M.P.H., Head of Development, will participate in the Stifel 2023 CNS Days. The webcast will be live on Tuesday, March 28, 2023, at 9:15 a.m. ET. To access the live webcast, please visit the Investors section of Biogen's website at [investors.biogen.com](#). An archived version of the webcast will be available for at least 90 days following the presentation.

About Biogen

Founded in 1978, Biogen is a leading global biotechnology company that has pioneered multiple breakthrough innovations including a broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy, and two co-developed treatments to address a defining pathology of Alzheimer's disease. Biogen is advancing a pipeline of potential novel therapies across neurology, neuropsychiatry, specialized immunology and rare diseases and remains acutely focused on its purpose of serving humanity through science while advancing a healthier, more sustainable and equitable world.

We routinely post information that may be important to investors on our website at [www.biogen.com](#).

Follow us on social media – [Twitter](#), [LinkedIn](#), [Facebook](#), [YouTube](#).

Contact:

Karen Jewell
Investor Relations
Biogen
781.464.2442